Int J Sports Med 2004; 25(8): 588-593
DOI: 10.1055/s-2004-821304
Clinical Sciences

© Georg Thieme Verlag KG Stuttgart · New York

Treatment of Muscle Injuries by Local Administration of Autologous Conditioned Serum: A Pilot Study on Sportsmen with Muscle Strains

T. Wright-Carpenter1 , 3 , P. Klein2 , P. Schäferhoff2 , H. J. Appell3 , L. M. Mir1 , P. Wehling4
  • 1UMR 8121 CNRS, Institut Gustave-Roussy, Villejuif, France
  • 2MediaPark Clinic for Sports Medicine & Orthopaedics, Köln, Germany
  • 3Department of Physiology & Anatomy, German Sport University, Köln, Germany
  • 4Orthopaedics and Neurosurgery Clinic, Düsseldorf, Germany
Further Information

Publication History

Publication Date:
28 September 2004 (online)

Abstract

Muscle injuries represent a major part of sports injuries and are a challenging problem in traumatology. Strain injuries are the most common muscle injuries after contusions. These injuries can lead to significant pain and disability causing time to be lost to training and competition. Despite the frequency of strain injuries the treatment available is limited and is generally not sufficient to enhance muscle regeneration efficiently when fast resumption of sport activity is a primary target. A number of growth factors play a specific role in regeneration and it has been proven that a previously described method of physically and chemically stimulating whole blood (to produce autologous conditioned serum) induces concentration increases in FGF-2, HGF, and TGF-β1. A preliminary study was conducted on muscle strain injuries in professional sportsmen receiving either: 1. autologous conditioned serum (ACS) or 2. Actovegin/Traumeel® treatment as control. Assessment of recovery from injury was done by: 1. sport professional's ability to participate to 100 % under competition conditions in their respective sport and 2. MRI analysis. A significant difference in the recovery time from injury was demonstrated: 16.6 ± 0.9 in the ACS treated instead of 22.3 ± 1.2 (mean ± SEM) days in the Actovegin/Traumeel® control group (p = 0.001). MRI analysis supported the observed acceleration of the lesion recovery time. We conclude that ACS injection is a promising approach to reduce the time to recovery from muscle injury.

References

L. M. Mir

Laboratory of Vectorology and Gene Transfer, UMR 8121 CNRS - Institut Gustave Roussy

39, rue Camille Desmoulins

94805 Villejuif Cedex

France

Phone: + 33(0)142114792

Fax: + 33 (0) 1 42 11 52 45

Email: luismir@igr.fr